Thus, anti-GPC-3 CAR T cells could potentially recognize GPC-3–expressing gliomas and GPC-3 antigens shed in the TME, which poses another target for glioma extracellular matrices that could be useful for dual CAR-targeting strategies. The gene discussed is GPC3; the disease is glioma.